$RKTO News

Rocket One Increases At The Market Equity Offering To Up To $6.83M In Additional Common Stock Sales Under Sales Agreement With H C Wainwright & Co

From biotech to orbit: Rocket One's AI and space rebrand sends shares flying

HOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Deals

Hoth Therapeutics Announces That Previously Disclosed Name Change To Rocket One, Trading Under Symbol 'RKTO,' To Take Effect May 28

Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)

AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Hoth Therapeutics Q1 EPS $(0.17) Up From $(0.27) YoY

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Hoth Therapeutics Secures Regulatory Authorization In Spain For Phase 2a CLEER Trial Of HT-001

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Hoth Therapeutics shares are trading higher after the company announced data from its HT-VA study.

Hoth Therapeutics shares are trading higher after the company announced data from its HT-VA study.

Hoth Therapeutics Announces Data From Its HT-VA Study Demonstrating That Parenteral GDNF Directly Reprograms Liver Fat Metabolism At The Genetic Level In A Preclinical Model of Metabolically Associated Fatty Liver Disease

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Hoth Therapeutics Announces $2M Direct Offering At $0.70/Shr

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six